New Label Warns Against Plavix with CYP2C19 Inhibitors, Raises Questions about Role of Mutations | GenomeWeb

By Turna Ray

The US Food and Drug Administration this week issued a new warning to healthcare providers and patients against the concomitant use of the anti-platelet agent Plavix (clopidogrel) and CYP2C19-inhibiting agents, but the agency simultaneously acknowledged that there are many unanswered questions about the link between Plavix response and CYP2C19 metabolism pending results from ongoing studies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.